Subjects n | 336 |
Age years | 53±13 |
Female | 55 |
BMI kg·m−2 | 28±5 |
Age at asthma onset years | 45±15 |
Asthma duration years | 3 (0–10) |
Current or ex-smoker | 54 |
Pack-years | 1 (0–13) |
ICS fluticasone equivalent µg | 500 (250–500) |
ACQ score | 1.3±0.8 |
Atopy | 32 |
Nasal polyposis | 19 |
Post-bronchodilator FEV1 % pred | 97±18 |
Post-bronchodilator FEV1/FVC % pred | 93±12 |
FeNO ppb | 23 (13–42) |
Total IgE kU·L−1 | 56 (18–216) |
Blood neutrophils ×109 cells·L−1 | 4.3±1.7 |
Blood eosinophils ×109 cells·L−1 | 0.2 (0.1–0.3) |
Sputum neutrophils % | 66.3 (45.4–82.3) |
Sputum eosinophils % | 0.8 (0.1–6.6) |
Data are presented as mean±sd, percentage or median (interquartile range), unless otherwise stated. BMI: body mass index; ICS: inhaled corticosteroid; ACQ: asthma control questionnaire; FEV1: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity; FeNO: exhaled nitric oxide fraction; Ig: immunoglobulin.